

Drug Monograph

Drug Name: **Apretude ER (cabotegravir) vial**
 Drug Class: **Anti-Infectives: Antiretroviral Therapy (ART)**
 Prepared For: MO HealthNet
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Apretude is supplied in a kit containing one 600 mg/3 mL single dose vial of cabotegravir extended-release injectable suspension, 1 syringe, 1 vial adapter, and 1 needle for intramuscular injection (23 gauge, 1½ inch).	
Manufacturer:	Manufactured for: ViiV Healthcare, Research Triangle Park, NC 27709.	
Indications:	Apretude is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test prior to initiating Apretude (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.	
Costs:	\$3,700 per 3 mL Wholesale Acquisition Cost	
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.	
Status Recommendation:	<input type="checkbox"/> Clinical Edit <input type="checkbox"/> Open Access	<input type="checkbox"/> PA Required <input checked="" type="checkbox"/> Preferred Drug List
Type of PA Criteria:	<input type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required	<input checked="" type="checkbox"/> Non-Preferred <input type="checkbox"/> Non-Reference

Prepared by: April Ash, PharmD
 Date: January 7, 2022